Skip to search formSkip to main contentSkip to account menu

AM 803

Known as: AM-803, GSK2190915 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The effect of GSK2190915, a 5-lipoxygenase-activating protein inhibitor, on exercise-induced bronchoconstriction.
Exercise-induced bronchoconstriction (EIB) describes the condition whereby exercise causes airflow obstruction that lasts for up… 
2014
2014
Exploring the roles of UGT1A1 and UGT1A3 in oral clearance of GSK2190915, a 5-lipoxygenase-activating protein inhibitor.
Pharmacokinetic variability in drug exposure is a concern for all compounds in development including those for the treatment of… 
Review
2014
Review
2014
From the Common Cough to Hereditary Angioedema
As illustrated within the pages of the current issue of the Proceedings, the specialty of allergy–immunology encompasses a… 
2013
2013
The 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma
GSK2190915, a potent 5‐lipoxygenase‐activating protein inhibitor, prevents the synthesis of leukotrienes and 5‐oxo‐6,8,11,14… 
2013
2013
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma
Abstract Objective: To investigate the clinical benefits of ‘add-on’ therapy with GSK2190915 in combination with the inhaled… 
2011
2011
The 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor GSK2190915 , Reduces Cigarette Smoke-Induced Pulmonary Inflammation In The Mouse
2011
2011
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response
Background: GSK2190915 is a potent 5-lipoxygenase activating protein inhibitor, thereby inhibiting the synthesis of leukotrienes… 
2011
2011
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen
Background: GSK2190915 is a potent 5-lipoxygenase activating protein inhibitor, thereby inhibiting the synthesis of leukotrienes… 
2011
2011
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2…
The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)